Icotrokinra Sustains High-Impact Psoriasis Site Clearance Through 2 Years
Phase 3 ICONIC-TOTAL data show oral icotrokinra achieved IGA 0/1 in 70% of psoriasis patients at Week 112, with 89% genital clearance and no new safety signals.
Topic
Iconic Total
Topic
Iconic Total
Icotrokinra Sustains High-Impact Site Clearance at 2 Years
Two-year ICONIC-TOTAL extension data show icotrokinra sustains clearance of high-impact psoriasis sites — scalp, face, palms, sol…